{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:21:20Z","timestamp":1792894880173,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2022-I2M-C&T-B-006, 2022-I2M-1-012"],"award-info":[{"award-number":["2022-I2M-C&T-B-006, 2022-I2M-1-012"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-A-037, 2022-PUMCH-B-013"],"award-info":[{"award-number":["2022-PUMCH-A-037, 2022-PUMCH-B-013"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2021YFC2702001"],"award-info":[{"award-number":["2021YFC2702001"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Natural Science Fund","award":["82071842"],"award-info":[{"award-number":["82071842"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Iguratimod (IGU) reduces hypergammaglobulinemia and disease activity in pSS (primary Sj\u00f6gren\u2019s syndrome) patients. However, the therapeutical mechanism of IGU for pSS remains largely unknown. This study aimed to investigate the regulation of Tfh cell differentiation by IGU in pSS patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We prospectively enrolled 13 pSS patients treated with IGU for 3\u00a0months and examined circulating T cell and B cell subsets by flow cytometry. We measured Tfh cell differentiation treated by IGU in pSS patients and healthy controls. Transcriptome analysis combined with molecular docking were employed to identify potential therapeutical targets of IGU, which were verified by Western blot and Tfh cell differentiation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Tfh, plasmablast, and plasma cells were suppressed by IGU treatment at 1 and 3\u00a0months. Tfh cell differentiation and function were significant inhibited by IGU in pSS patients and healthy controls in vitro. Pyruvate dehydrogenase kinase 1 (PDK1) was identified as a target of IGU during Tfh cell differentiation, and the downstream Akt phosphorylation was attenuated by IGU. Moreover, the activity of mTORC1 and phosphorylation of STAT3 were suppressed by IGU, with downregulation of <jats:italic>BCL6<\/jats:italic> and upregulation of <jats:italic>PRDM1.<\/jats:italic> Finally, Akt activator restored IGU-suppressed Tfh cell differentiation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IGU suppresses Tfh cell differentiation in pSS patients through interacting with PDK1 and suppressing Akt-mTOR-STAT3 signaling.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03109-4","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:01:56Z","timestamp":1692702116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Iguratimod suppresses Tfh cell differentiation in primary Sj\u00f6gren\u2019s syndrome patients through inhibiting Akt\/mTOR\/STAT3 signaling"],"prefix":"10.1186","volume":"25","author":[{"given":"Taibiao","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuting","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengmei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaowen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"issue":"9482","key":"3109_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox RI. Sj\u00f6gren\u2019s syndrome. Lancet (London, England). 2005;366(9482):321\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(05)66990-5.","journal-title":"Lancet (London, England)"},{"issue":"10","key":"3109_CR2","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.autrev.2018.05.005","volume":"17","author":"K Psianou","year":"2018","unstructured":"Psianou K, Panagoulias I, Papanastasiou AD, de Lastic AL, Rodi M, Spantidea PI, et al. Clinical and immunological parameters of Sj\u00f6gren\u2019s syndrome. Autoimmun Rev. 2018;17(10):1053\u201364. https:\/\/doi.org\/10.1016\/j.autrev.2018.05.005.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"3109_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Bombardieri S, Bootsma H, De Vita S, D\u00f6rner T, et al. EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216114.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3109_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","volume":"14","author":"G Nocturne","year":"2018","unstructured":"Nocturne G, Mariette X. B cells in the pathogenesis of primary Sj\u00f6gren syndrome. Nat Rev Rheumatol. 2018;14(3):133\u201345. https:\/\/doi.org\/10.1038\/nrrheum.2018.1.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"3109_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/m13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Pu\u00e9chal X, et al. Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233\u201342. https:\/\/doi.org\/10.7326\/m13-1085.","journal-title":"Ann Intern Med"},{"issue":"10320","key":"3109_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0140-6736(21)02251-0","volume":"399","author":"SJ Bowman","year":"2022","unstructured":"Bowman SJ, Fox R, D\u00f6rner T, Mariette X, Papas A, Grader-Beck T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet (London, England). 2022;399(10320):161\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(21)02251-0.","journal-title":"Lancet (London, England)"},{"issue":"5","key":"3109_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","volume":"78","author":"T D\u00f6rner","year":"2019","unstructured":"D\u00f6rner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, et al. Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis. 2019;78(5):641\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214720.","journal-title":"Ann Rheum Dis"},{"issue":"suppl","key":"3109_CR8","first-page":"9","volume":"74","author":"DZS Xu","year":"2022","unstructured":"Xu DZS, Huang C, Huang C, Qin L, Li X, Chen M, Liu X, Liu Y, Li Z, Hu J, Bao C. Wei w, Tian J, Duan X, Fang J, Zeng X: Efficacy and safety of Telitacicept in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Arthritis Rheumatol. 2022;74(suppl):9.","journal-title":"Arthritis Rheumatol"},{"key":"3109_CR9","unstructured":"D\u00f6rner TSA, Tseng J, Kaul M, Pylvaenaeinen I, Hanser M, Abdallah N, Cenni B, Siegel R. Remibrutinib (LOU064) in Sj\u00f6gren\u2019s syndrome: safety and efficacy results from a 24-week placebo-controlled proof-of-concept study. Arthritis Rheumatol. 2022;74(suppl):9."},{"issue":"2","key":"3109_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/14397595.2018.1460230","volume":"29","author":"T Mimori","year":"2019","unstructured":"Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, et al. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: final report of a 52-week, multicenter postmarketing surveillance study. Mod Rheumatol. 2019;29(2):314\u201323. https:\/\/doi.org\/10.1080\/14397595.2018.1460230.","journal-title":"Mod Rheumatol"},{"issue":"11","key":"3109_CR11","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1007\/s10792-020-01490-6","volume":"40","author":"W Jiang","year":"2020","unstructured":"Jiang W, Zhang L, Zhao Y, He X, Hu C, Liu Y. The efficacy and mechanism for action of iguratimod in primary Sj\u00f6gren\u2019s syndrome patients. Int Ophthalmol. 2020;40(11):3059\u201365. https:\/\/doi.org\/10.1007\/s10792-020-01490-6.","journal-title":"Int Ophthalmol"},{"issue":"2","key":"3109_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/03009742.2020.1809701","volume":"50","author":"Q Shao","year":"2021","unstructured":"Shao Q, Wang S, Jiang H, Liu L. Efficacy and safety of iguratimod on patients with primary Sj\u00f6gren\u2019s syndrome: a randomized, placebo-controlled clinical trial. Scand J Rheumatol. 2021;50(2):143\u201352. https:\/\/doi.org\/10.1080\/03009742.2020.1809701.","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"3109_CR13","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","volume":"50","author":"S Crotty","year":"2019","unstructured":"Crotty S. T follicular helper cell biology: a decade of discovery and diseases. Immunity. 2019;50(5):1132\u201348. https:\/\/doi.org\/10.1016\/j.immuni.2019.04.011.","journal-title":"Immunity"},{"key":"3109_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-120419-022408","volume":"40","author":"GD Victora","year":"2022","unstructured":"Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2022;40:413\u201342. https:\/\/doi.org\/10.1146\/annurev-immunol-120419-022408.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"3109_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/imr.12860","volume":"296","author":"MA Mintz","year":"2020","unstructured":"Mintz MA, Cyster JG. T follicular helper cells in germinal center B cell selection and lymphomagenesis. Immunol Rev. 2020;296(1):48\u201361. https:\/\/doi.org\/10.1111\/imr.12860.","journal-title":"Immunol Rev"},{"issue":"10","key":"3109_CR16","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ni.3554","volume":"17","author":"JS Weinstein","year":"2016","unstructured":"Weinstein JS, Herman EI, Lainez B, Licona-Lim\u00f3n P, Esplugues E, Flavell R, et al. TFH cells progressively differentiate to regulate the germinal center response. Nat Immunol. 2016;17(10):1197\u2013205. https:\/\/doi.org\/10.1038\/ni.3554.","journal-title":"Nat Immunol"},{"issue":"2","key":"3109_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1084\/jem.20091738","volume":"207","author":"MA Linterman","year":"2010","unstructured":"Linterman MA, Beaton L, Yu D, Ramiscal RR, Srivastava M, Hogan JJ, et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med. 2010;207(2):353\u201363. https:\/\/doi.org\/10.1084\/jem.20091738.","journal-title":"J Exp Med"},{"issue":"5","key":"3109_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20090313","volume":"206","author":"IL King","year":"2009","unstructured":"King IL, Mohrs M. IL-4-producing CD4+ T cells in reactive lymph nodes during helminth infection are T follicular helper cells. J Exp Med. 2009;206(5):1001\u20137. https:\/\/doi.org\/10.1084\/jem.20090313.","journal-title":"J Exp Med"},{"issue":"1","key":"3109_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","volume":"34","author":"R Morita","year":"2011","unstructured":"Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34(1):108\u201321. https:\/\/doi.org\/10.1016\/j.immuni.2010.12.012.","journal-title":"Immunity"},{"issue":"4","key":"3109_CR20","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.4110\/in.2019.19.e26","volume":"19","author":"JW Kim","year":"2019","unstructured":"Kim JW, Lee J, Hong SM, Lee J, Cho ML, Park SH. Circulating CCR7(lo)PD-1(hi) follicular helper T cells indicate disease activity and glandular inflammation in patients with primary Sj\u00f6gren\u2019s syndrome. Immune Netw. 2019;19(4):e26. https:\/\/doi.org\/10.4110\/in.2019.19.e26.","journal-title":"Immune Netw"},{"issue":"2","key":"3109_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.bbrc.2012.04.133","volume":"422","author":"XY Li","year":"2012","unstructured":"Li XY, Wu ZB, Ding J, Zheng ZH, Li XY, Chen LN, et al. Role of the frequency of blood CD4(+) CXCR5(+) CCR6(+) T cells in autoimmunity in patients with Sj\u00f6gren\u2019s syndrome. Biochem Biophys Res Commun. 2012;422(2):238\u201344. https:\/\/doi.org\/10.1016\/j.bbrc.2012.04.133.","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"3109_CR22","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1136\/annrheumdis-2020-217646","volume":"79","author":"E Pontarini","year":"2020","unstructured":"Pontarini E, Murray-Brown WJ, Croia C, Lucchesi D, Conway J, Rivellese F, et al. Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sj\u00f6gren\u2019s syndrome with ectopic germinal centres and MALT lymphoma. Ann Rheum Dis. 2020;79(12):1588\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217646.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3109_CR23","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/art.40424","volume":"70","author":"VR Fonseca","year":"2018","unstructured":"Fonseca VR, Rom\u00e3o VC, Agua-Doce A, Santos M, L\u00f3pez-Presa D, Ferreira AC, et al. The ratio of blood T follicular regulatory cells to T follicular helper cells marks ectopic lymphoid structure formation while activated follicular helper T cells indicate disease activity in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 2018;70(5):774\u201384. https:\/\/doi.org\/10.1002\/art.40424.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"3109_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clim.2013.02.024","volume":"147","author":"K Szabo","year":"2013","unstructured":"Szabo K, Papp G, Barath S, Gyimesi E, Szanto A, Zeher M. Follicular helper T cells may play an important role in the severity of primary Sj\u00f6gren\u2019s syndrome. Clin Immunol. 2013;147(2):95\u2013104. https:\/\/doi.org\/10.1016\/j.clim.2013.02.024.","journal-title":"Clin Immunol"},{"issue":"W1","key":"3109_CR25","doi-asserted-by":"publisher","first-page":"W356","DOI":"10.1093\/nar\/gkx374","volume":"45","author":"X Wang","year":"2017","unstructured":"Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017;45(W1):W356-w360. https:\/\/doi.org\/10.1093\/nar\/gkx374.","journal-title":"Nucleic Acids Res"},{"key":"3109_CR26","doi-asserted-by":"publisher","first-page":"e61406","DOI":"10.7554\/eLife.61406","volume":"10","author":"Z Sun","year":"2021","unstructured":"Sun Z, Yao Y, You M, Liu J, Guo W, Qi Z, et al. The kinase PDK1 is critical for promoting T follicular helper cell differentiation. Elife. 2021;10:e61406. https:\/\/doi.org\/10.7554\/eLife.61406.","journal-title":"Elife"},{"issue":"1","key":"3109_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-019-1874-2","volume":"21","author":"Y Ye","year":"2019","unstructured":"Ye Y, Liu M, Tang L, Du F, Liu Y, Hao P, et al. Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC\/EGR1 axis. Arthritis Res Ther. 2019;21(1):92. https:\/\/doi.org\/10.1186\/s13075-019-1874-2.","journal-title":"Arthritis Res Ther"},{"key":"3109_CR28","doi-asserted-by":"publisher","first-page":"356040","DOI":"10.1155\/2015\/356040","volume":"2015","author":"Y Xu","year":"2015","unstructured":"Xu Y, Zhu Q, Song J, Liu H, Miao Y, Yang F, et al. Regulatory effect of iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis. Mediators Inflamm. 2015;2015:356040. https:\/\/doi.org\/10.1155\/2015\/356040.","journal-title":"Mediators Inflamm"},{"key":"3109_CR29","doi-asserted-by":"publisher","first-page":"757616","DOI":"10.3389\/fimmu.2022.757616","volume":"13","author":"Z Bai","year":"2022","unstructured":"Bai Z, Lu Z, Liu R, Tang Y, Ye X, Jin M, et al. Iguratimod restrains circulating follicular helper T cell function by inhibiting glucose metabolism via Hif1\u03b1-HK2 axis in rheumatoid arthritis. Front Immunol. 2022;13:757616. https:\/\/doi.org\/10.3389\/fimmu.2022.757616.","journal-title":"Front Immunol"},{"issue":"8","key":"3109_CR30","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41590-022-01253-8","volume":"23","author":"D Yu","year":"2022","unstructured":"Yu D, Walker LSK, Liu Z, Linterman MA, Li Z. Targeting T(FH) cells in human diseases and vaccination: rationale and practice. Nat Immunol. 2022;23(8):1157\u201368. https:\/\/doi.org\/10.1038\/s41590-022-01253-8.","journal-title":"Nat Immunol"},{"key":"3109_CR31","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","volume":"2","author":"A Kaul","year":"2016","unstructured":"Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. https:\/\/doi.org\/10.1038\/nrdp.2016.39.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"3109_CR32","first-page":"2591","volume":"28","author":"M Kohno","year":"2001","unstructured":"Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol. 2001;28(12):2591\u20136.","journal-title":"J Rheumatol"},{"issue":"6478","key":"3109_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/369327a0","volume":"369","author":"F Pag\u00e8s","year":"1994","unstructured":"Pag\u00e8s F, Ragueneau M, Rottapel R, Truneh A, Nunes J, Imbert J, et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature. 1994;369(6478):327\u20139. https:\/\/doi.org\/10.1038\/369327a0.","journal-title":"Nature"},{"issue":"2","key":"3109_CR34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ni.1687","volume":"10","author":"SG Park","year":"2009","unstructured":"Park SG, Schulze-Luehrman J, Hayden MS, Hashimoto N, Ogawa W, Kasuga M, et al. The kinase PDK1 integrates T cell antigen receptor and CD28 coreceptor signaling to induce NF-kappaB and activate T cells. Nat Immunol. 2009;10(2):158\u201366. https:\/\/doi.org\/10.1038\/ni.1687.","journal-title":"Nat Immunol"},{"issue":"6","key":"3109_CR35","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.immuni.2017.11.008","volume":"47","author":"K Essig","year":"2017","unstructured":"Essig K, Hu D, Guimaraes JC, Alterauge D, Edelmann S, Raj T, et al. Roquin suppresses the PI3K-mTOR signaling pathway to inhibit T helper cell differentiation and conversion of Treg to Tfr cells. Immunity. 2017;47(6):1067-1082.e1012. https:\/\/doi.org\/10.1016\/j.immuni.2017.11.008.","journal-title":"Immunity"},{"issue":"4","key":"3109_CR36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41423-021-00660-5","volume":"18","author":"X Huang","year":"2021","unstructured":"Huang X, Hao S, Liu J, Huang Y, Liu M, Xiao C, et al. The ubiquitin ligase Peli1 inhibits ICOS and thereby Tfh-mediated immunity. Cell Mol Immunol. 2021;18(4):969\u201378. https:\/\/doi.org\/10.1038\/s41423-021-00660-5.","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"3109_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.semcdb.2003.12.022","volume":"15","author":"A Mora","year":"2004","unstructured":"Mora A, Komander D, van Aalten DM, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol. 2004;15(2):161\u201370. https:\/\/doi.org\/10.1016\/j.semcdb.2003.12.022.","journal-title":"Semin Cell Dev Biol"},{"issue":"9","key":"3109_CR38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ni.2947","volume":"15","author":"N Schmitt","year":"2014","unstructured":"Schmitt N, Liu Y, Bentebibel SE, Munagala I, Bourdery L, Venuprasad K, et al. The cytokine TGF-\u03b2 co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells. Nat Immunol. 2014;15(9):856\u201365. https:\/\/doi.org\/10.1038\/ni.2947.","journal-title":"Nat Immunol"},{"issue":"5943","key":"3109_CR39","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1126\/science.1175870","volume":"325","author":"RJ Johnston","year":"2009","unstructured":"Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science. 2009;325(5943):1006\u201310. https:\/\/doi.org\/10.1126\/science.1175870.","journal-title":"Science"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03109-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03109-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03109-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:49:07Z","timestamp":1700527747000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03109-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3109"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03109-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"assertion":[{"value":"18 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board of PUMCH (No. HS-1112), and written informed consent was obtained from all subjects in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}